Three‐dimensional EPI with shot‐selective CAIPIRIHANA for rapid high‐resolution quantitative susceptibility mapping at 3 T.

Saved in:
Bibliographic Details
Title: Three‐dimensional EPI with shot‐selective CAIPIRIHANA for rapid high‐resolution quantitative susceptibility mapping at 3 T.
Authors: Tourell, Monique1,2 (AUTHOR) m.tourell@uq.edu.au, Jin, Jin2,3 (AUTHOR), Bachrata, Beata4,5,6 (AUTHOR), Stewart, Ashley2,7 (AUTHOR), Ropele, Stefan8 (AUTHOR), Enzinger, Christian8 (AUTHOR), Bollmann, Saskia7 (AUTHOR), Bollmann, Steffen2,7 (AUTHOR), Robinson, Simon Daniel1,4,8,9 (AUTHOR), O'Brien, Kieran2,3 (AUTHOR), Barth, Markus1,2,7 (AUTHOR)
Source: Magnetic Resonance in Medicine. Sep2024, Vol. 92 Issue 3, p997-1010. 14p.
Subjects: Brain injuries, Brain tumors, Neurodegeneration
Abstract: Purpose: QSM provides insight into healthy brain aging and neuropathologies such as multiple sclerosis (MS), traumatic brain injuries, brain tumors, and neurodegenerative diseases. Phase data for QSM are usually acquired from 3D gradient‐echo (3D GRE) scans with long acquisition times that are detrimental to patient comfort and susceptible to patient motion. This is particularly true for scans requiring whole‐brain coverage and submillimeter resolutions. In this work, we use a multishot 3D echo plannar imaging (3D EPI) sequence with shot‐selective 2D CAIPIRIHANA to acquire high‐resolution, whole‐brain data for QSM with minimal distortion and blurring. Methods: To test clinical viability, the 3D EPI sequence was used to image a cohort of MS patients at 1‐mm isotropic resolution at 3 T. Additionally, 3D EPI data of healthy subjects were acquired at 1‐mm, 0.78‐mm, and 0.65‐mm isotropic resolution with varying echo train lengths (ETLs) and compared with a reference 3D GRE acquisition. Results: The appearance of the susceptibility maps and the susceptibility values for segmented regions of interest were comparable between 3D EPI and 3D GRE acquisitions for both healthy and MS participants. Additionally, all lesions visible in the MS patients on the 3D GRE susceptibility maps were also visible on the 3D EPI susceptibility maps. The interplay among acquisition time, resolution, echo train length, and the effect of distortion on the calculated susceptibility maps was investigated. Conclusion: We demonstrate that the 3D EPI sequence is capable of rapidly acquiring submillimeter resolutions and providing high‐quality, clinically relevant susceptibility maps. [ABSTRACT FROM AUTHOR]
Copyright of Magnetic Resonance in Medicine is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Engineering Source
Full text is not displayed to guests.
Description
Abstract:Purpose: QSM provides insight into healthy brain aging and neuropathologies such as multiple sclerosis (MS), traumatic brain injuries, brain tumors, and neurodegenerative diseases. Phase data for QSM are usually acquired from 3D gradient‐echo (3D GRE) scans with long acquisition times that are detrimental to patient comfort and susceptible to patient motion. This is particularly true for scans requiring whole‐brain coverage and submillimeter resolutions. In this work, we use a multishot 3D echo plannar imaging (3D EPI) sequence with shot‐selective 2D CAIPIRIHANA to acquire high‐resolution, whole‐brain data for QSM with minimal distortion and blurring. Methods: To test clinical viability, the 3D EPI sequence was used to image a cohort of MS patients at 1‐mm isotropic resolution at 3 T. Additionally, 3D EPI data of healthy subjects were acquired at 1‐mm, 0.78‐mm, and 0.65‐mm isotropic resolution with varying echo train lengths (ETLs) and compared with a reference 3D GRE acquisition. Results: The appearance of the susceptibility maps and the susceptibility values for segmented regions of interest were comparable between 3D EPI and 3D GRE acquisitions for both healthy and MS participants. Additionally, all lesions visible in the MS patients on the 3D GRE susceptibility maps were also visible on the 3D EPI susceptibility maps. The interplay among acquisition time, resolution, echo train length, and the effect of distortion on the calculated susceptibility maps was investigated. Conclusion: We demonstrate that the 3D EPI sequence is capable of rapidly acquiring submillimeter resolutions and providing high‐quality, clinically relevant susceptibility maps. [ABSTRACT FROM AUTHOR]
ISSN:07403194
DOI:10.1002/mrm.30101